News stories about CVS Health Corporation (NYSE:CVS) have been trending somewhat positive recently, according to Accern. The research group ranks the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. CVS Health Corporation earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned news headlines about the pharmacy operator an impact score of 84 out of 100, indicating that recent press coverage is very likely to have an impact on the company’s share price in the next several days.
These are some of the news stories that may have effected Accern Sentiment’s scoring:
- Jul 06, 2017 – First PREMIER Bank Buys CVS Health Corp, Lamar … – GuruFocus.com (gurufocus.com)
- CVS Health Corporation (CVS) Given Financial News Affect Recommendation of 0.37 – Insider Tradings (insidertradings.org)
- CVS: Critical Reality Check – Seeking Alpha (seekingalpha.com)
- Could a Reckoning at Rite Aid Spark an Amazon.com Acquisition? (finance.yahoo.com)
- Shares Trading down at $79.00 (CVS) CVS Health Corporation Announces… (healthcaremenu.net)
Several research firms recently issued reports on CVS. Vetr downgraded shares of CVS Health Corporation from a “strong-buy” rating to a “buy” rating and set a $85.96 price target for the company. in a research note on Tuesday, May 23rd. Guggenheim reissued a “buy” rating and set a $90.00 target price on shares of CVS Health Corporation in a research report on Tuesday, March 28th. Leerink Swann set a $90.00 price target on shares of CVS Health Corporation and gave the stock a “buy” rating in a report on Saturday, March 18th. Tigress Financial started coverage on shares of CVS Health Corporation in a research note on Thursday, April 27th. They issued a “buy” rating on the stock. Finally, ValuEngine cut shares of CVS Health Corporation from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Nine equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $93.98.
Shares of CVS Health Corporation (NYSE CVS) traded down 0.09% on Friday, hitting $78.64. 3,442,497 shares of the company traded hands. The firm has a market capitalization of $80.12 billion, a P/E ratio of 16.40 and a beta of 0.91. CVS Health Corporation has a 1-year low of $69.30 and a 1-year high of $98.66. The firm’s 50-day moving average is $78.46 and its 200 day moving average is $79.38.
CVS Health Corporation (NYSE:CVS) last issued its earnings results on Tuesday, May 2nd. The pharmacy operator reported $1.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.10 by $0.07. CVS Health Corporation had a return on equity of 17.56% and a net margin of 2.86%. The business had revenue of $44.51 billion during the quarter, compared to the consensus estimate of $44.20 billion. During the same period last year, the company earned $1.18 EPS. The company’s revenue for the quarter was up 3.0% on a year-over-year basis. On average, analysts anticipate that CVS Health Corporation will post $5.87 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, August 3rd. Shareholders of record on Monday, July 24th will be given a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 2.54%. The ex-dividend date is Thursday, July 20th. CVS Health Corporation’s dividend payout ratio is currently 41.67%.
In other news, CFO David M. Denton sold 230,510 shares of CVS Health Corporation stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $80.00, for a total value of $18,440,800.00. Following the completion of the transaction, the chief financial officer now owns 176,983 shares in the company, valued at approximately $14,158,640. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Helena Foulkes sold 20,333 shares of CVS Health Corporation stock in a transaction dated Monday, June 26th. The shares were sold at an average price of $80.00, for a total value of $1,626,640.00. Following the completion of the transaction, the executive vice president now owns 59,301 shares of the company’s stock, valued at approximately $4,744,080. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 271,175 shares of company stock valued at $21,632,597. 0.61% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: This piece of content was posted by BBNS and is the sole property of of BBNS. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at https://baseballnewssource.com/markets/cvs-health-corporation-cvs-earning-somewhat-favorable-news-coverage-report-shows-updated-updated/1043672.html.
About CVS Health Corporation
CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.
Receive News & Ratings for CVS Health Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corporation and related companies with our FREE daily email newsletter.